Brief: PCI Biotech granted orphan drug designation from FDA for Fimaporfin

PCI Biotech Holding ASA

04/10/2017 17:11

Oct 4 (Reuters) - Pci Biotech Holding Asa  PCIB.OL  
    * Says the U.S. food  and drug administration (FDA) has 
granted Orphan drug designation to its lead product candidate, 
Fimaporfin, a drug that treats patients suffering from 
Cholangiocarcinoma (bile duct cancer)  
    * Says Orphan designation is a "significant regulatory 
milestone" and that it "supports further development of FimaChem 
in this indication and provides important development and 
commercialisation benefits" 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nGNE9YCpCq 
Further company coverage:  PCIB.OL  
 
 (Reporting By Joachim Dagenborg) 
 ((joachim.dagenborg@thomsonreuters.com;))